Serum cell‐free DNA as a new biomarker in cutaneous T‐cell lymphoma
Serum cell‐free DNA as a new biomarker in cutaneous T‐cell lymphoma
复制标题
DOI：
10.1111/1346-8138.16520
复制
发表时间：
2022-07
期刊：
影响因子：
--
通讯作者：
Yuka Mizuno;S. Shibata;T. Miyagaki;Y. Ito;H. Taira;I. Omori;T. Hisamoto;K. Oka;K. Matsuda;H. Boki;N. Takahashi-Shishido;M. Sugaya;S. Sato
中科院分区：
文献类型：
--
作者：
Yuka Mizuno;S. Shibata;T. Miyagaki;Y. Ito;H. Taira;I. Omori;T. Hisamoto;K. Oka;K. Matsuda;H. Boki;N. Takahashi-Shishido;M. Sugaya;S. Sato
近年来，循环无细胞DNA（cfDNA）作为各种癌症的生物标志物受到了极大的关注。许多报道已经表明，癌症患者的血清cfDNA水平升高，并且其水平与预后和疾病活动相关。本研究的目的是测量皮肤T细胞淋巴瘤（CTCL）患者的血清cfDNA水平，并评估其与血液学和临床结果的相关性。CTCL患者血清cfDNA水平显著高于健康对照组，且随着疾病分期的进展，其水平逐渐升高。检测到血清cfDNA水平与乳酸脱氢酶、胸腺和活化调节趋化因子和可溶性IL-2受体以及外周血中性粒细胞和嗜酸性粒细胞计数和中性粒细胞/淋巴细胞比值之间呈正相关。此外，具有较高血清cfDNA水平的CTCL患者表现出显著较差的预后。总之，这些结果表明cfDNA作为反映CTCL预后和疾病活动性的新生物标志物的潜力。CfDNA水平可以作为考虑后续治疗干预的强度和时机的指标。
In recent years, circulating cell‐free DNA (cfDNA) has received a great attention as a biomarker for various cancers. Many reports have shown that serum cfDNA levels are elevated in cancer patients and their levels correlate with prognosis and disease activity. The aim of this study was to measure serum cfDNA levels in patients with cutaneous T‐cell lymphoma (CTCL) and to evaluate their correlations with hematological and clinical findings. Serum cfDNA levels in CTCL patients were significantly higher than those in healthy controls, and their levels gradually increased with the progression of the disease stage. Positive correlations were detected between serum cfDNA levels and those of lactate dehydrogenase, thymus and activation‐regulated chemokine and soluble IL‐2 receptor as well as neutrophil and eosinophil count in peripheral blood and neutrophil‐to‐lymphocyte ratio. Furthermore, CTCL patients with higher serum cfDNA levels exhibited a significantly worse prognosis. Taken together, these results suggest the potential of cfDNA as a new biomarker reflecting prognosis and disease activity in CTCL. CfDNA levels may serve as an indicator for considering the intensity and timing of subsequent therapeutic intervention.